Skip to Content
Merck
All Photos(1)

Documents

Y0000808

Sodium phenylbutyrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C10H11NaO2
CAS Number:
Molecular Weight:
186.18
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

sodium phenylbutyrate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1

InChI key

VPZRWNZGLKXFOE-UHFFFAOYSA-M

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Sodium phenylbutyrate is a histone deacetylase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
A F List
Leukemia research, 22 Suppl 1, S7-11 (1998-09-12)
Norihiko Yokoi et al.
Nature medicine, 21(1), 19-26 (2014-12-09)
Epilepsy is one of the most common and intractable brain disorders. Mutations in the human gene LGI1, encoding a neuronal secreted protein, cause autosomal dominant lateral temporal lobe epilepsy (ADLTE). However, the pathogenic mechanisms of LGI1 mutations remain unclear. We
Masayuki Koyama et al.
American journal of physiology. Heart and circulatory physiology, 306(9), H1314-H1323 (2014-03-13)
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and vascular remodeling of the pulmonary artery (PA). Recently, endoplasmic reticulum (ER) stress and inappropriate adaptation through the unfolded protein response (UPR) have been disclosed in various types of diseases. Here we
Sotaro Naoi et al.
The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)
To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile
Elisabeth Kemter et al.
The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)
Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service